Please login to the form below
White paper for download: The vicious circle of pharmaceutical tendering
In this white paper, we discuss the pros of tendering, including cost reduction, but also the cons, such as supply issues and aggressive bidding consequences. Plus, our expert offers guidance on how to navigate the vicious circle.
With the tendering process becoming increasingly important in pharmaceutical procurement, accounting for around 25% of total global pharmaceutical turnover, it’s important to understand the impacts and risks that could affect you. In this white paper, we discuss the pros of tendering, including cost reduction, but also the cons, such as supply issues and aggressive bidding consequences. Plus, our expert offers guidance on how to navigate the vicious circle.
Download the white paper now for insight into:
- What tendering entails
- The importance of tendering for pharma
- The effect of epoetin tendering
- How the ‘winner takes all’ pricing game works
- The risks that create a vicious circle of tendering
Download the white paper here: https://www.validinsight.com/resource-center/the-vicious-circle-of-pharmaceutical-tendering/
Company Details
Valid Insight
Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom
Latest content on this profile
- Valid Insight are hiring for Consultants in Value Communication (mid to senior levels)
- New role available for Consultants in Value Communication with experience in market access writing and value communication.
Valid Insight
- Webinar: Maintaining market access through a pandemic, 6 months on
- In this webinar, Valid Insight explore market access and how it has evolved through a pandemic over the past 6 months.
Valid Insight
- Webinar: How to develop an optimal value story for your product
- This webinar is part of the ongoing expert insights series run by Valid Insight
Valid Insight
- Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
- How can you ensure your product achieves optimal market access during a global economic recession?
Valid Insight
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen.
Valid Insight
- Why are new medicinal products denied reimbursement in France?
- Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative to alternative treatments for successful market access. In this blog, we summarise the reasons for negative reimbursement decisions in 2017 and discuss common pitfalls manufacturers should avoid.
Valid Insight
